Drug Pricing Germany Plus H3
and milligram prices of parental solutions
Drug Pricing Germany Plus H3 in a nutshell
The Drug Pricing Germany Plus H3 is an optional supplement to the Drug Pricing Tool Germany and contains all the information required for the milligram pricing of parenteral solutions in accordance with Appendix 3 of the Price Listing of Substances and Preparations from Substances (Auxiliary Tax).
The most important information in the Drug Pricing Germany Plus H3 :
- Pharmaceutical Central Number (PZN)
- Milligram prices, possibly case-related (aut idem allowed / not allowed)
- Billing factors to be used in the calculation
- Details of the information relevant to the calculation of the substances: e.g. the fabric quantity per PZN, molar mass of the fabric, etc.
- Groupings of carrier solutions (subgroups) with prices and discount factors
- Information regarding the settlement of liquidators in accordance with Appendix 3 Part 1 Annexes 1 to 3 with details of the factor for calculating the discard limit and the period of time
Suitable for:
Pharma Industry, Pharma Trade, Health Insurance, Regulatory
Source: AVOXA ABDATA
Eschborn, Germany
Related subscription
This database can be accessed after purchasing the subscription package ‘Drug Pricing’ or ‘Premium’
These databases could also be intersting for you
Related posts
Drug Pricing Database Germany: A One-Stop Solution for Up-to-Date Pharmaceutical Prices
Drug pricing database Germany – these four words sum up a critical need in the pharmaceutical industry. In a market as regulated and dynamic as Germany’s, professionals across market access, pharmacovigilance, hospital pharmacy, and health insurance face the constant...
Pharma Pricing Germany: Navigating Costs, Compliance and Transparency
Pharmaceutical pricing in Germany is unique in Europe – offering initial free pricing yet governed by strict mechanisms like AMNOG benefit assessments, reference pricing, and rebate contracts. In this comprehensive guide, we explain pharma pricing in Germany for...
Pharmaceutical Market Access Germany: Navigating Approval, Pricing, and Reimbursement
Pharmaceutical market access in Germany is a critical step for any drug developer aiming to tap into Europe’s largest pharmaceutical market. With a population of 84 million and annual pharmaceutical revenues exceeding €56.9 billion in 2021, Germany offers vast...
